Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation | Zendy

M Bonduelle | Zendy; Janine Oberyé | Zendy; Bernadette Mannaerts | Zendy; Paul Devroey | Zendy

Open Access

Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation

Author(s) -

M Bonduelle,

Janine Oberyé,

Bernadette Mannaerts,

Paul Devroey

Publication year - 2010

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/deq072

Subject(s) - pregnancy , medicine , obstetrics , fetus , gestation , randomized controlled trial , gynecology , biology , genetics

A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects. To demonstrate long-term safety of ganirelix (GnRH antagonist) treatment in controlled ovarian stimulation (COS), follow-up data on pregnancy and neonatal outcome were analysed for 1000 fetuses (>or=16 gestational weeks).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research